Lantz Financial’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.13M | Sell |
46,747
-454
| -1% | -$11.9K | 0.21% | 116 |
|
|
2026
Q1 | $1.33M | Buy |
47,201
+819
| +2% | +$21.8K | 0.27% | 101 |
|
|
2025
Q4 | $1.15M | Buy |
46,382
+1,058
| +2% | +$26.7K | 0.24% | 104 |
|
|
2025
Q3 | $1.15M | Buy |
45,324
+10,042
| +28% | +$248K | 0.26% | 105 |
|
|
2025
Q2 | $855K | Buy |
35,282
+2,621
| +8% | +$61.1K | 0.21% | 109 |
|
|
2025
Q1 | $828K | Buy |
32,661
+1,097
| +3% | +$28.7K | 0.23% | 107 |
|
|
2024
Q4 | $837K | Sell |
31,564
-32
| -0.1% | -$868 | 0.22% | 103 |
|
|
2024
Q3 | $914K | Buy |
31,596
+2,363
| +8% | +$68.9K | 0.25% | 93 |
|
|
2024
Q2 | $818K | Sell |
29,233
-1,349
| -4% | -$37.1K | 0.25% | 96 |
|
|
2024
Q1 | $849K | Buy |
30,582
+381
| +1% | +$10.6K | 0.27% | 90 |
|
|
2023
Q4 | $869K | Buy |
30,201
+171
| +0.6% | +$5.17K | 0.31% | 81 |
|
|
2023
Q3 | $996K | Buy |
30,030
+1,165
| +4% | +$41.2K | 0.4% | 71 |
|
|
2023
Q2 | $1.06M | Sell |
28,865
-1,281
| -4% | -$49.9K | 0.41% | 70 |
|
|
2023
Q1 | $1.23M | Buy |
30,146
+3,040
| +11% | +$131K | 0.51% | 64 |
|
|
2022
Q4 | $1.39M | Buy |
27,106
+1,601
| +6% | +$76.8K | 0.63% | 48 |
|
|
2022
Q3 | $1.12M | Buy |
25,505
+152
| +0.6% | +$7.39K | 0.58% | 53 |
|
|
2022
Q2 | $1.33M | Sell |
25,353
-981
| -4% | -$50K | 0.6% | 53 |
|
|
2022
Q1 | $1.36M | Sell |
26,334
-32,170
| -55% | -$1.67M | 0.55% | 55 |
|
|
2021
Q4 | $3.46M | Sell |
58,504
-369
| -0.6% | -$18.3K | 1.59% | 11 |
|
|
2021
Q3 | $2.53M | Sell |
58,873
-1,281
| -2% | -$56.7K | 1.3% | 12 |
|
|
2021
Q2 | $2.36M | Buy |
60,154
+1,835
| +3% | +$71.4K | 1.21% | 12 |
|
|
2021
Q1 | $2.11M | Buy |
58,319
+1,399
| +2% | +$49.7K | 1.2% | 15 |
|
|
2020
Q4 | $2.1M | Sell |
56,920
-5,243
| -8% | -$192K | 1.31% | 14 |
|
|
2020
Q3 | $2.16M | Buy |
62,163
+1,443
| +2% | +$50.6K | 1.46% | 11 |
|
|
2020
Q2 | $1.88M | Sell |
60,720
-4,420
| -7% | -$150K | 1.36% | 11 |
|
|
2020
Q1 | $2.02M | Buy |
65,140
+2,062
| +3% | +$70.3K | 1.58% | 10 |
|
|
2019
Q4 | $2.35M | Buy |
63,078
+2,039
| +3% | +$72.6K | 1.39% | 11 |
|
|
2019
Q3 | $2.01M | Buy |
61,039
+1,284
| +2% | +$46.7K | 1.36% | 11 |
|
|
2019
Q2 | $2.51M | Buy |
59,755
+376
| +0.6% | +$14.9K | 1.7% | 7 |
|
|
2019
Q1 | $2.39M | Buy |
+59,379
| New | +$2.38M | 1.74% | 8 |
|
Other funds holding PFE
Lantz Financial's PFE Position: Q2 2026 in Review
Lantz Financial reduced its Pfizer (PFE) stake by 0.96% in Q2 2026, selling an estimated $11.9K and leaving 46,747 shares worth $1.13M. The position accounts for 0.21% of the portfolio, ranked #116.
Lantz Financial first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $3.46M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Lantz Financial held 46,747 shares of Pfizer worth $1.13M as of Q2 2026.
- Lantz Financial sold 454 Pfizer shares in Q2 2026, an estimated $11.9K.
- Pfizer made up 0.21% of Lantz Financial's portfolio in Q2 2026, its #116 holding.
- Lantz Financial first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
- Lantz Financial's Pfizer position peaked at $3.46M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Lantz Financial's 13F filing for Q2 2026, filed 9 Jul 2026.